Clinigen appoints experienced pharma leader Paul Carter as Non-Executive Chair to drive next phase of strategic growth

London, UK, 12 June 2025 –  Clinigen, the global specialist pharmaceutical services Group, has appointed seasoned biopharma executive Paul Carter as Non-Executive Chair of its Board. This appointment strengthens the Board and positions Clinigen for its next phase of growth and ongoing transformation as it continues to expand and deliver increased value across the full pharmaceutical lifecycle for clients, healthcare professionals, and patients.  

Paul brings unparalleled commercial and strategic expertise to Clinigen, with nearly 30 years of global biopharmaceutical industry leadership experience. He has lived and worked extensively across North America, Europe, and Asia, building a proven track record in strategic commercial and leadership roles. His experience includes serving as Executive Vice President and Chief Commercial Officer at Gilead Sciences where he oversaw global commercial operations, international expansion across 38 markets, and $30 billion in annual revenue. He also held senior leadership roles including Head of GlaxoSmithKline China and Head of SmithKline Beecham Russia.  

Alongside his executive career, Paul has built an extensive portfolio of board and advisory roles. He currently serves as Chair of the Memo Therapeutics AG Board and, separately, the Kyowa Kirin International PLC Board, a subsidiary of Kyowa Kirin Co., Ltd. (TSE: 4151), and is also Board Director at Immatics NV (NASDAQ: IMTX). Beyond this, Paul advises several global healthcare investors and innovative life sciences companies, including Astorg Partners, Concentric Analgesics Inc. and Magdalen Medical Publishing Ltd. He also advises and coaches senior BioPharma executives via GLG Institute and Pioneering Collective. 

Over his career spanning a diverse range of therapeutic areas, commercial models, and international markets, Paul has built and scaled operations worldwide, overseen the launch of market-leading pharmaceutical products, and led the development of strategic global partnerships - all of which will be instrumental as Clinigen enters its next phase of transformation and growth, in its journey to become the world’s premier end-to-end lifecycle partner for pharmaceutical and biotech companies, from clinical services to commercialisation and regulatory solutions. 

Jerome Charton, CEO commented, “Paul Carter's appointment as Chair represents a significant milestone for Clinigen as we continue our strategic transformation, and his visionary leadership and unparalleled experience in global pharmaceutical commercialisation and will be instrumental in executing our ambitious growth strategy. We’re thrilled to welcome him as we enter this next phase - strengthening our offering, innovating to add value for our partners, and ensuring patients get faster ethical access to the medicines they need.” 

Paul Carter, non-executive board chair, also commented, “I am incredibly excited to join Clinigen at such a dynamic time in its journey. The company has a unique and essential role to play in improving access to innovative medicines worldwide. I look forward to working with the Board and management team to strengthen our strategic foundations, accelerate our transformation, and help unlock the next phase of growth and success, delivering exceptional value to clients and patients.” 

Paul’s appointment follows the recent strengthening of Clinigen’s operational leadership team and a series of strategic acquisitions to further enhance its specialist capabilities across the pharmaceutical lifecycle. These include Drug Safety Navigator, Ascenian Consulting, and Kinesys Consulting, strengthening the Group’s expertise in market access and regulatory affairs, as well as a minority stake in Tepsivo, an AI-powered pharmacovigilance platform. Together, these moves reinforce Clinigen’s commitment to delivering smarter, more integrated solutions for clients and patients worldwide.